Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07033845
Recruiting Early Phase 1

Pharmacokinetic Study of Topical Phenylephrine

NCT07033845 · tracked via the Priya Life Science Italy tracker
Sponsor
Applied Biology, Inc
Phase
Early Phase 1
Started
2025-06-30
Last updated
2025-10-03

Condition(s) studied

Chemotherapy Induced AlopeciaChemotherapy Side Effects

Investigational drug(s) / intervention(s)

Phenylephrine

Phenylephrine: Topical Phenylephrine

Study summary

Pharmacokinetic Study of Topical Phenylephrine

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy females, age 18-55 * BMI: 18-30 kg/m² * Fitzpatrick Skin Types I-IV (to standardize absorption risk) * Scalp free from irritation, dermatologic disease, or damage * Able to refrain from using other topical scalp products Exclusion Criteria: * History of cardiovascular disease, hypertension, or arrhythmia * Scalp infections, wounds, or significant hair loss * Recent use of medications that interfere with CYP enzymes or adrenergic systems * Known sensitivity to phenylephrine or ethanol * Positive drug screen or abnormal ECG at screening

Primary outcome measure(s)

  • Pharmacokinetic profile of phenylephrine — Week [0,3]
    Determine the amount of phenylephrine and its metabolites in serum daily scalp application of topical phenylephrine for a period of 3 weeks

Trial sites (1)

FacilityCityRegionStatus
University of Rome ("G. Marconi") Rome Italy Recruiting

More Applied Biology, Inc. trials in Italy

Pharmacokinetic Study of DA-020 Starting soon
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia Recruiting
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Starting soon

Other trials for the same condition

Pharmacokinetic Study of DA-020 Starting soon
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia Recruiting
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07033845 on ClinicalTrials.gov ↗ ← All trials in Italy